By contrast, the expression of VEGFB and VEGFD was related to a better prognosis across the three cancers: VEGFB was a favorable prognostic factor for esophageal carcinoma (ESCA), pancreatic adenocarcinoma (PAAD), and sarcoma (SARC); and VEGFD was a favorable prognostic factor for LUAD, PAAD, and SARC. Here, VEGFB is linked to cancer.